Clinical Trial Update: A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating risankizumab as maintenance therapy for adults with moderate to severe plaque psoriasis; results have been completed and posted in Dece…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2024-12-11